Table 3

Summary of patient immunotherapy-related adverse events by patient group

GroupAllP value*
CtrlIBD
N (%)N (%)N (%)
irAEs†
 No73 (48.67)11 (36.67)84 (46.67)0.32
 Yes77 (51.33)19 (63.33)96 (53.33)
ICI stop reason
 Colitis6 (4)7 (23.33)13 (7.22)0.04
 Disease progression51 (34)8 (26.67)59 (32.78)
 Other irAE23 (15.33)6 (20)29 (16.11)
 Death32 (21.33)4 (13.33)36 (20)
 Complete remission1 (0.67)0 (0)1 (0.56)
 Still receiving23 (15.33)5 (16.67)28 (15.56)
 Infection5 (3.33)0 (0)5 (2.78)
 Treatment break9 (6)0 (0)9 (5)
ICI stop reason (condensed)
 N/A (still receiving)23 (15.33)5 (16.67)28 (15.56)
 All other reasons98 (65.33)12 (40)110 (61.11)0.006
 irAE (including imDC)29 (19.33)13 (43.33)42 (23.33)
  • IBD and control cohorts were propensity score matched by cancer type, cancer mediation, and age.

  • *P values by Fisher’s exact test.

  • †ICI colitis and ICI diarrhea were analyzed as time-to-event endpoints and were not included in this table.

  • IBD, inflammatory bowel disease; ICI, immune checkpoint inhibitor; imDC, immune-mediated diarrhea and colitis; irAE, immune-related adverse events.